Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura M Jacobsen

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Diabetes Technology & Therapeutics|March 17, 2025
Immune Intervention and Replacement Therapies in Type 1 DiabetesLaura M Jacobsen, Nataša Bratina, Desmond Schatz
MLO: Medical Laboratory Observer|July 14, 2018
Insulin, insulin antibodies and insulin autoantibodiesWilliam E Winter, Laura M Jacobsen, David Pittman
Pediatric Diabetes|January 26, 2018
Presymptomatic screening for autoimmune β-cell disorder: Baby steps toward prevention?Laura M Jacobsen, Henry Anhalt, Michael J Haller
Frontiers in Endocrinology|March 22, 2018
Understanding Pre-Type 1 Diabetes: The Key to PreventionLaura M Jacobsen, Michael J Haller, Desmond A Schatz
Diabetes Spectrum : a Publication of the American Diabetes Association|August 16, 2023
Type 1 Diabetes Continuous Glucose Monitoring Use in the Pediatric Emergency Department Affects Laboratory Test Frequency but Not Treatment TimingRachel K Baker, Stephanie L Filipp, Laura M Jacobsen
The Lancet. Diabetes & Endocrinology|November 28, 2024
Time to reframe the disease staging system for type 1 diabetesLaura M Jacobsen, Mark A Atkinson, Jay M Sosenko, et al.
Diabetes Care|June 23, 2016
Presumptive Type 1 Diabetes With Comorbidities and Rapid Progression Despite Numerous Insulin-Positive IsletsLaura M Jacobsen, Mark A Atkinson, Martha Campbell-Thompson, et al.
Diabetes|February 26, 2021
How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?Michael J Haller, Laura M Jacobsen, Amanda L Posgai, et al.
Diabetes Care|August 25, 2016
Diagnostic Dilemma: Clinical and Histological Abnormalities in a Hispanic Patient With DiabetesLaura M Jacobsen, Amanda L Posgai, Martha Campbell-Thompson, et al.
Diabetes Technology & Therapeutics|October 27, 2021
Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 DiabetesHai V Nguyen, Desmond A Schatz, Shweta Mital, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Diabetes Technology & Therapeutics|March 17, 2025
Immune Intervention and Replacement Therapies in Type 1 DiabetesLaura M Jacobsen, Nataša Bratina, Desmond Schatz
MLO: Medical Laboratory Observer|July 14, 2018
Insulin, insulin antibodies and insulin autoantibodiesWilliam E Winter, Laura M Jacobsen, David Pittman
Pediatric Diabetes|January 26, 2018
Presymptomatic screening for autoimmune β-cell disorder: Baby steps toward prevention?Laura M Jacobsen, Henry Anhalt, Michael J Haller
Frontiers in Endocrinology|March 22, 2018
Understanding Pre-Type 1 Diabetes: The Key to PreventionLaura M Jacobsen, Michael J Haller, Desmond A Schatz
Diabetes Spectrum : a Publication of the American Diabetes Association|August 16, 2023
Type 1 Diabetes Continuous Glucose Monitoring Use in the Pediatric Emergency Department Affects Laboratory Test Frequency but Not Treatment TimingRachel K Baker, Stephanie L Filipp, Laura M Jacobsen
The Lancet. Diabetes & Endocrinology|November 28, 2024
Time to reframe the disease staging system for type 1 diabetesLaura M Jacobsen, Mark A Atkinson, Jay M Sosenko, et al.
Diabetes Care|June 23, 2016
Presumptive Type 1 Diabetes With Comorbidities and Rapid Progression Despite Numerous Insulin-Positive IsletsLaura M Jacobsen, Mark A Atkinson, Martha Campbell-Thompson, et al.
Diabetes|February 26, 2021
How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?Michael J Haller, Laura M Jacobsen, Amanda L Posgai, et al.
Diabetes Care|August 25, 2016
Diagnostic Dilemma: Clinical and Histological Abnormalities in a Hispanic Patient With DiabetesLaura M Jacobsen, Amanda L Posgai, Martha Campbell-Thompson, et al.
Diabetes Technology & Therapeutics|October 27, 2021
Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 DiabetesHai V Nguyen, Desmond A Schatz, Shweta Mital, et al.
Pageof 8